Is ORPOF or RYLD a better dividend investment in 2026?

ORPOF currently yields 17.24% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: ORPOF offers higher current income.

What is the dividend yield difference between ORPOF and RYLD?

ORPOF has a forward dividend yield of 17.24% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 5.10 percentage points.

Home › Compare › ORPOF vs RYLD

ORPOF vs RYLD: Dividend Comparison 2026

ORPOF yields 17.24% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ORPOF wins by $17.0K in total portfolio value

INVESTMENT

TIME HORIZON10 years

ORPOF

● Live price

17.24%

Share price

$11.60

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$61.6K

Annual income

$4,960.97

Full ORPOF calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — ORPOF vs RYLD

📍 ORPOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ORPOF	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ORPOF + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ORPOF pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORPOF

Annual income on $10K today (after 15% tax)

$1,465.52/yr

After 10yr DRIP, annual income (after tax)

$4,216.82/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, ORPOF beats the other by $2,017.58/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORPOF + RYLD for your $10,000?

ORPOF: 50%RYLD: 50%

100% RYLD50/50100% ORPOF

Portfolio after 10yr

$53.0K

Annual income

$3,774.16/yr

Blended yield

7.12%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORPOF buys

RYLD buys

No recent congressional trades found for ORPOF or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricORPOFRYLD

Forward yield	17.24% ✓	12.14%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$61.6K ✓	$44.5K
Annual income after 10y	$4,960.97 ✓	$2,587.35
Total dividends collected	$32.3K ✓	$18.8K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ORPOF vs RYLD ($10,000, DRIP)

Year	ORPOF Portfolio	ORPOF Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$12,424	$1,724.14	$11,914	$1,213.65	+$510.00 → ORPOF
2	$15,296	$2,001.96	$14,099	$1,351.30	+$1.2K → ORPOF
3	$18,670	$2,303.44	$16,580	$1,494.55	+$2.1K → ORPOF
4	$22,604	$2,627.62	$19,384	$1,642.61	+$3.2K → ORPOF
5	$27,160	$2,973.25	$22,535	$1,794.70	+$4.6K → ORPOF
6	$32,400	$3,338.74	$26,063	$1,950.00	+$6.3K → ORPOF
7	$38,390	$3,722.32	$29,995	$2,107.69	+$8.4K → ORPOF
8	$45,200	$4,121.99	$34,361	$2,266.99	+$10.8K → ORPOF
9	$52,899	$4,535.61	$39,194	$2,427.12	+$13.7K → ORPOF
10	$61,563	$4,960.97	$44,525	$2,587.35	+$17.0K → ORPOF

ORPOF vs RYLD: Complete Analysis 2026

ORPOF — Stock

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.

Full ORPOF Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this ORPOF vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORPOF vs SCHD ORPOF vs JEPI ORPOF vs O ORPOF vs KO ORPOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.